



Neuroendocrine Neoplasia: From Pathophysiology to Novel Therapeutic Approaches

Guest Editor:

Dr. Mara Carsote

1. Department of Endocrinology,
Carol Davila University of
Medicine and Pharmacy, 050474
Bucharest, Romania
2. Department of Endocrinology,
C.I. Parhon National Institute of
Endocrinology, 011863
Bucharest, Romania

Deadline for manuscript
submissions:

closed (31 January 2024)

Message from the Guest Editor

Dear Colleagues,

The field of neuroendocrine neoplasia represents one of the most dynamic domains of modern medicine. New insights concerning pathophysiology of the tumors have been developed from genetic and epigenetic mechanisms, syndromic circumstances, and innovative biomarkers. The multimodal approach varies depending on the tumor site, grading, hormonal profile, co-morbidities, and access to modern therapeutic tools. From surgery to medical therapy with somatostatin analogues or mTOR inhibitors to PRRT and immunotherapy, the management is complex, and it requires excellence in multidisciplinary approaches.

Dr. Mara Carsote

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI